Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Squamous Cell Carcinoma of the Head and Neck (SCCHN) Clinical Trial

Official title:
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether the combination of palbociclib with cetuximab is superior to cetuximab in prolonging overall survival in HPV-negative, cetuximab-naive patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Clinical Trial Details

NCT number	NCT02499120
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 2
Start date	September 10, 2015
Completion date	September 7, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01204099` - Study of PX-866 and Docetaxel in Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT04989387` - Study of INCA 0186 in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT00392665` - Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck	Phase 2
Active, not recruiting	`NCT05057247` - Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC	Phase 2
Completed	`NCT02001623` - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors	Phase 1/Phase 2
Terminated	`NCT01285635` - A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck	Phase 2
Completed	`NCT03538028` - A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies	Phase 1
Completed	`NCT02335918` - A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors	Phase 1/Phase 2
Terminated	`NCT04052204` - Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT03405142` - Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer	Phase 2